Our previous studies showed that vasoconstrictor applied topically to rat skin minutes before irradiation completely prevented radiodermatitis. Here we report on a Phase IIa study of topically applied NG12-1 vasoconstrictor to prevent radiodermatitis in post-lumpectomy breast cancer patients who received at least 40 Gray to the whole breast using standard regimens.
Patients had undergone surgery for Stage Ia, Ib, or IIa infiltrating ductal or lobular carcinoma of the breast or ductal carcinoma in situ. NG12-1 formulation was applied topically to the same 50-cm2 treatment site within the radiation field 20 min before each daily radiotherapy fraction.
Scores indicated significant reductions in radiodermatitis at the NG12-1 treatment site versus control areas in the same radiotherapy field. The mean dermatitis score for all subjects was 0.47 (SD 0.24) in the NG12-1-treated area versus 0.72 (SD 0.22) in the control area (P = 0.022). Analysis by two independent investigators indicated radiodermatitis reductions in 9 of the 9 patients with scorable radiodermatitis severity, and one patient with insufficient radiodermatitis to enable scoring. There were no serious adverse events from NG12-1 treatment.
Thirty, daily, NG12-1 treatments, topically applied minutes before radiotherapy, were well tolerated and conferred statistically significant reductions in radiodermatitis severity (P = 0.022).
Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Statistics Factsheets: Breast Cancer. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/breast.htm.
Porock D, Kristjanson L. Skin reactions during radiotherapy for breast cancer: the use and impact of topical agents and dressings. Eur J Cancer Care. 1999;8:143–53. CrossRef
Hendry JH, Bentzen SM, Dale RG, Fowler JF, Wheldon TE, Jones B, Munro AJ, Slevin NJ, Robertson AG. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol. 1996;8:297–307. CrossRef
Bese NS, Sut PA, Sut N, Ober A. The impact of treatment interruptions on locoregional control during postoperative breast irradiation. J BUON. 2007;12:353–9. PubMed
Häfner ME, Fetzner L, Hassel JC, Debus J, Potthoff K. Prophylaxis of acute radiation dermatitis with an innovative FDA-approved two-step skin care system in a patient with head and neck cancer undergoing a platin-based radiochemotherapy:a case report and review of the literature. Dermatology. 2013;227:171–4. CrossRefPubMed
Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton L, Lazo J, Parker K, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006. p. 237–96.
Lichter AS. Radiation therapy. In: Abeloff MD, Armitage JO, Lichter AS, et al., editors. Clinical oncology. New York: Churchill Livingstone; 1995. p. 219–64.
- Significant suppression of radiation dermatitis in breast cancer patients using a topically applied adrenergic vasoconstrictor
James F. Cleary
Bethany M. Anderson
Jens C. Eickhoff
William E. Fahl
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II